HIV-Associated Lipodystrophy Treatment Market Application 2020 – Industry Overview, Global Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2026
SEATTLE, March 17, 2021, (PHARMIWEB) — HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms, and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients, who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of lipodystrophy in people infected with HIV varies between 10% and 80%.
Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/1269
Increasing prevalence of HIV is expected to drive growth of the HIV-associated lipodystrophy treatment market
According to an article published in Journal of AIDS & Clinical Research in 2014, prevalence of lipodystrophy in patients suffering from HIV varies significantly and was estimated between 32.4% and 88.6%. According to World Health Organization (WHO), in 2017, over 35 million people suffered from HIV worldwide and around 1.0 million people died from HIV in 2016. Increasing prevalence of HIV is expected to drive growth of the HIV-associated lipodystrophy market, as most (32.4%-88.6%) of the people suffering from HIV also suffer from HIV-associated lipodystrophy.
Approval of novel drugs in key regions such as North America is expected to drive growth of the HIV-Associated Lipodystrophy market. For instance, in 2014, Theratechnologies Inc. received approval from Health Canada for EGRIFTA. It is a growth hormone-releasing factor (GRF) for the treatment of HIV-associated lipodystrophy. EGRIFTA also received the U.S. Food and Drug Administration (FDA) approval in 2010. Such approval of new drugs in the key region is expected to drive growth of the HIV-associated lipodystrophy treatment market.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Quick Buy – HIV-Associated Lipodystrophy Treatment Market Research Report: https://bit.ly/3bSBL32
Global HIV-Associated Lipodystrophy Treatment Market Taxonomy
The global HIV-associated lipodystrophy treatment market is segmented on the basis of lipodystrophy type, therapeutic class, and distribution channel.
On the basis of lipodystrophy type, the global HIV-associated lipodystrophy treatment market is segmented into:
- Lipoatrophy
- Lipoaccumulation
On the basis of therapeutic class, the global HIV-associated lipodystrophy treatment market is segmented into:
- Anabolism Modulators
- Growth Hormones
- Anabolic Steroids
- Insulin Resistance Modulators
- Metformins
- Thiazolidinediones
- Mitochondrial Antioxidants (l-carnitine)
- Others
On the basis of the distribution channel, the global HIV-associated lipodystrophy treatment market is segmented into:
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/1269
North America is expected to hold a dominant position in HIV-associated lipodystrophy treatment market, owing to favorable insurance policy mandating insurance companies to cover HIV-related lipodystrophy
North America is expected to hold a dominant position in HIV-related lipodystrophy treatment market, owing to favorable insurance policy. In 2016, The Massachusetts House and Senate approved a bill mandating insurance coverage to treat HIV drug side-effects such as HIV-related lipodystrophy. Approval of such insurance policy is expected to create a lucrative environment for HIV-related lipodystrophy market. Europe is expected to be the second largest market in HIV-related lipodystrophy market due to high prevalence of HIV in Europe. For instance, according to an article published in National Center for Biotechnology Information (NCBI) in 2014, around 860,000 adults were living with HIV in Europe and the highest prevalence of HIV were found in France (17.7 %), Spain (13.1 %), Greece (12.7 %) and Germany (11.5 %).
According to The Joint United Nations Programme on HIV and AIDS (UNAIDS), about 36.7 million were living with HIV globally, and 30% of these people were unaware about their condition in 2016. Out of this 36.7 million people, 19.4 million were living in East and Southern Africa. The higher prevalence of HIV in region such as Africa has limited access to drugs for disease such as HIV-associated lipodystrophy is expected to be major restraining factor in this market.
Major market players of HIV-associated lipodystrophy treatment market
Key players operating in global HIV-associated lipodystrophy treatment market include Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc., AstraZeneca plc, AbbVie Inc., and Bristol-Myers Squibb.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Application
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- PEST Analysis
- Market Dynamics
- Global HIV-Associated Lipodystrophy Treatment – Impact of Coronavirus (Covid-19) Pandemic
- COVID-19 Epidemiology
- Safety Syringes for COIVD-19 Vaccines
- Global HIV-Associated Lipodystrophy Treatment Market, By Product Type, 2016 – 2027, (US$ Mn)
- Global HIV-Associated Lipodystrophy Treatment Market, By Application, 2016 – 2027, (US$ Mn)
- Global HIV-Associated Lipodystrophy Treatment Market, By End User, 2016 – 2027, (US$ Mn)
- Global HIV-Associated Lipodystrophy Treatment Market, By Region, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2027
- North America
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
